DGIdb - SULINDAC Drug Record

SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

Alternate Names:

CLINORIL
MK-231
SULINDAC
CIS-5-FLUORO-2-METHYL-1-((P-METHYLSULFINYL)BENZYLIDENE)INDENE-3-ACETIC ACID
CIS-5-FLUORO-2-METHYL-1-((4-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
SULINDACUM
(Z)-5-FLUORO-2-METHYL-1-((P-(METHYLSULFINYL)PHENYL)METHYLENE)-1H-INDENE-3-ACETIC ACID
SULINDACO
CLINORIL®
chembl:CHEMBL15770
pubchem.compound:1548887
rxcui:10237
chemidplus:38194-50-2
drugbank:00605

Drug Info:

Drug Class	anti-inflammatory agents, non-steroidal
Year of Approval	1978
Drug Categories	therapeutic uses
Drug Categories	sensory system agents
Drug Categories	polycyclic hydrocarbons, aromatic
Drug Categories	polycyclic compounds
Drug Categories	physiological effects of drugs
Drug Categories	pharmacologic actions
Drug Categories	peripheral nervous system agents
Drug Categories	organic chemicals
Drug Categories	musculo-skeletal system
Drug Categories	molecular mechanisms of pharmacological action
Drug Categories	indenes
Drug Categories	hydrocarbons, cyclic
Drug Categories	hydrocarbons, aromatic
Drug Categories	hydrocarbons
Drug Categories	enzyme inhibitors
Drug Categories	cytochrome p-450 cyp1a2 inhibitors
Drug Categories	cyclooxygenase inhibitors
Drug Categories	chemical actions and uses
Drug Categories	central nervous system agents
Drug Categories	antirheumatic agents
Drug Categories	antineoplastic agents
Drug Categories	antiinflammatory and antirheumatic products, non-steroids
Drug Categories	antiinflammatory and antirheumatic products
Drug Categories	anti-inflammatory agents, non-steroidal
Drug Categories	anti-inflammatory agents
Drug Categories	analgesics, non-narcotic
Drug Categories	analgesics
Drug Categories	acetic acid derivatives and related substances
Drug Groups	approved
Drug Type	small molecule
FDA Approval	1978
Drug Class	small molecule
Drug Indications	NSAID
Drug Categories	photosensitizing agents
Drug Categories	other nonsteroidal anti-inflammatory agents
Drug Categories	oat1/slc22a6 inhibitors
Drug Categories	non cox-2 selective nsaids
Drug Categories	nephrotoxic agents
Drug Categories	drugs causing inadvertant photosensitivity
Drug Categories	anti-inflammatory agents, non-steroidal (non-selective)
Drug Categories	agents that produce hypertension
Drug Categories	agents causing hyperkalemia
Drug Groups	investigational

(7 More Sources)

Publications:

Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.
Yip-Schneider et al., 2000, Cyclooxygenase-2 expression in human pancreatic adenocarcinomas., Carcinogenesis
Fosslien, 2000, Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia., Crit Rev Clin Lab Sci
Taylor et al., 2000, Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells., Cancer Res.
Molina et al., 1999, Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs., Cancer Res.
Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis
Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.
Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.
Soriano et al., 1999, Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines., Cancer Res.
Cheng et al., 2002, Vascular effects of COX inhibition and AT1 receptor blockade in transgenic rats harboring mouse renin-2 gene., J. Physiol. Pharmacol.
Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem
Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol
van der Sloot et al., 1995, Sulindac in established experimental diabetes: a follow-up study., Can J Neurol Sci
Sharma et al., Topical sulindac therapy in diabetic senile cataracts: cataract-IV., Indian J Ophthalmol
Jacobson et al., 1983, Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors., Invest. Ophthalmol. Vis. Sci.
Chaudhry et al., 1983, Inhibition of human lens aldose reductase by flavonoids, sulindac and indomethacin., Biochem. Pharmacol.
Crabbe et al., 1985, The inhibition of bovine lens aldose reductase by Clinoril, its absorption into the human red cell and its effect on human red cell aldose reductase activity., Ophthalmic Res.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Jarvis et al., 2005, Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line., Oncogene
Kim et al., 2006, Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)., Carcinogenesis
Babbar et al., 2003, Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer., J. Biol. Chem.
He et al., 1999, PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs., Cell
Liou et al., 2007, Nonsteroidal anti-inflammatory drugs induce colorectal cancer cell apoptosis by suppressing 14-3-3epsilon., Cancer Res.
Yip-Schneider et al., Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac., J. Gastrointest. Surg.
Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med
Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
Hata et al., 2005, Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2., Mol. Pharmacol.
Rice et al., 2003, Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells., Cancer Res.
Pangburn et al., 2005, Sulindac metabolites inhibit epidermal growth factor receptor activation and expression., J Carcinog
Rice et al., 2004, Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites., Cancer Res.
Rice et al., 2001, Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites., Cancer Res.
Rice et al., 2006, Sulindac independently modulates extracellular signal-regulated kinase 1/2 and cyclic GMP-dependent protein kinase signaling pathways., Mol. Cancer Ther.
Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.
Cousido-Siah A et al., 2015, Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10., Chem Biol Interact

SULINDAC PTGS2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

Publications:

Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.

Yip-Schneider et al., 2000, Cyclooxygenase-2 expression in human pancreatic adenocarcinomas., Carcinogenesis

Fosslien, 2000, Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia., Crit Rev Clin Lab Sci

SULINDAC PTGS1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Publications:

Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.

Lim et al., 1999, Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines., Biochem. Pharmacol.

Cheng et al., 2003, Cardiovascular and renal effects of cyclooxygenase inhibition in transgenic rats harboring mouse renin-2 gene (TGR[mREN2]27)., Eur. J. Pharmacol.

SULINDAC RXRA

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Publications:

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

SULINDAC AKR1B1

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

van der Sloot et al., 1995, Sulindac in established experimental diabetes: a follow-up study., Can J Neurol Sci

Sharma et al., Topical sulindac therapy in diabetic senile cataracts: cataract-IV., Indian J Ophthalmol

Jacobson et al., 1983, Diabetic complications in lens and nerve and their prevention by sulindac or sorbinil: two novel aldose reductase inhibitors., Invest. Ophthalmol. Vis. Sci.

SULINDAC PPARD

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Info:

Publications:

Jarvis et al., 2005, Both PPARgamma and PPARdelta influence sulindac sulfide-mediated p21WAF1/CIP1 upregulation in a human prostate epithelial cell line., Oncogene

Kim et al., 2006, Inhibition of chemically induced skin carcinogenesis by sulindac is independent of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta)., Carcinogenesis

Babbar et al., 2003, Cyclooxygenase-independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer., J. Biol. Chem.

SULINDAC PTGDR2

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Publications:

Hata et al., 2005, Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2., Mol. Pharmacol.

SULINDAC MAPK3

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Rice et al., 2003, Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells., Cancer Res.

Pangburn et al., 2005, Sulindac metabolites inhibit epidermal growth factor receptor activation and expression., J Carcinog

Rice et al., 2004, Inhibition of extracellular-signal regulated kinases 1/2 is required for apoptosis of human colon cancer cells in vitro by sulindac metabolites., Cancer Res.

SULINDAC AKR1B10

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Publications:

Cousido-Siah A et al., 2015, Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10., Chem Biol Interact
SULINDAC APC

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

Publications:

Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

SULINDAC PIK3CA

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung non-small cell carcinoma

Response Type predicted - sensitive

Approval Status Preclinical - Cell culture

Publications:

Yip-Schneider et al., Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac., J. Gastrointest. Surg.

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

SULINDAC TNFRSF10A

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.

SULINDAC CYP1A2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
SULINDAC CYP2D6

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
SULINDAC TAC1

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol

SULINDAC BIRC5

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.

Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer

SULINDAC CYP3A4

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
SULINDAC CYP2C9

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
SULINDAC MYC

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.
SULINDAC CYP2C19

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
SULINDAC FMO3

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
SULINDAC EHMT2

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:
SULINDAC KDM4E

Interaction Types & Directionality:

n/a

Interaction Info:

Publications:

DrugBank: DB00605

Version: 5.1.7

Alternate Names:

SULINDAC DrugBank Drug Name

38194-50-2 CAS Number

Apo-sulin Tab 150mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Yip-Schneider et al., 2000, Cyclooxygenase-2 expression in human pancreatic adenocarcinomas., Carcinogenesis

Giuliano et al., 1999, Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs., Br. J. Pharmacol.

Taylor et al., 2000, Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells., Cancer Res.

TEND: SULINDAC
- Version: 01-August-2011
Alternate Names:

SULINDAC Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class anti-inflammatory agents, non-steroidal

Publications:
TdgClinicalTrial: SULINDAC
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval 1978

Publications:

NCI: SULINDAC

Version: 14-September-2017

Alternate Names:

C850 NCI drug code

Drug Info:

Publications:

Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer

Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.

Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

DTC: SULINDAC

Version: 02-September-2020

Alternate Names:

CHEMBL15770 ChEMBL Drug ID

Drug Info:

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

JAX-CKB: Sulindac

Version: 15-September-2020

Alternate Names:

Drug Info:

Publications:

Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

Hedberg ML et al., 2019, Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for <i>PIK3CA</i>-altered head and neck cancer., J Exp Med

GuideToPharmacologyInteractions: 178102078
- Version: 20-July-2020
Alternate Names:

SULINDAC GuideToPharmacology Ligand Name

Drug Info:

Publications:
TTD: Sulindac
- Version: 2020.06.01
Alternate Names:

D0Z5IU TTD Drug ID

Drug Info:

Publications:
ChemblInteractions: CHEMBL15770
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL15770
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
PharmGKB: sulindac
- Version: 18-August-2020
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target
Mechanism of Interaction	Cyclooxygenase inhibitor

Direct Interaction?	False
Endogenous Drug?	False
Specific Action of the Ligand	Inhibition

Evidence Type	Actionable
Approval Status	Preclinical
Response Type	sensitive

Indication/Tumor Type	lung non-small cell carcinoma
Response Type	predicted - sensitive
Approval Status	Preclinical - Cell culture

SULINDAC	DrugBank Drug Name
38194-50-2	CAS Number
Apo-sulin Tab 150mg	Drug Brand

SULINDAC Drug Record

SULINDAC chembl:CHEMBL15770 ApprovedAntineoplastic

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target Mechanism of Interaction Cyclooxygenase inhibitor

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Inhibition

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Direct Interaction? False Endogenous Drug? False Specific Action of the Ligand Antagonist

Publications: Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: negative modulator (inhibitory)

Interaction Info:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

Publications: Hata et al., 2005, Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2., Mol. Pharmacol.

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

Publications: Cousido-Siah A et al., 2015, Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10., Chem Biol Interact

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical Response Type sensitive

Publications: Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

Interaction Types & Directionality: n/a

Interaction Info: Indication/Tumor Type lung non-small cell carcinoma Response Type predicted - sensitive Approval Status Preclinical - Cell culture

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

Interaction Types & Directionality: n/a

Interaction Info:

Publications: Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for &gt;200 compounds., Chem Res Toxicol

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Publications:

DrugBank: DB00605

Alternate Names: SULINDAC DrugBank Drug Name 38194-50-2 CAS Number Apo-sulin Tab 150mg Drug Brand

Drug Info: Drug Type small molecule Drug Groups approved Drug Groups investigational

TEND: SULINDAC

Alternate Names: SULINDAC Primary Drug Name

Drug Info: Year of Approval 1978 Drug Class anti-inflammatory agents, non-steroidal

Publications:

TdgClinicalTrial: SULINDAC

Alternate Names:

Drug Info: Drug Indications NSAID Drug Class small molecule FDA Approval 1978

Publications:

NCI: SULINDAC

Alternate Names: C850 NCI drug code

Drug Info:

DTC: SULINDAC

Alternate Names: CHEMBL15770 ChEMBL Drug ID

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

Mechanism of Interaction Cyclooxygenase inhibitor

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Inhibition

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Direct Interaction? False

Endogenous Drug? False

Specific Action of the Ligand Antagonist

Publications:

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

negative modulator (inhibitory)

Interaction Types & Directionality:

antagonist (inhibitory)

Publications:

Hata et al., 2005, Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2., Mol. Pharmacol.

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Types & Directionality:

inhibitor (inhibitory)

Publications:

Cousido-Siah A et al., 2015, Structural analysis of sulindac as an inhibitor of aldose reductase and AKR1B10., Chem Biol Interact

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical

Response Type sensitive

Publications:

Itano et al., 2009, Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations., Carcinogenesis

Interaction Types & Directionality:

n/a

Interaction Info:

Indication/Tumor Type lung non-small cell carcinoma

Response Type predicted - sensitive

Approval Status Preclinical - Cell culture

Interaction Types & Directionality:

n/a

Publications:

Koornstra et al., 2005, Sulindac inhibits beta-catenin expression in normal-appearing colon of hereditary nonpolyposis colorectal cancer and familial adenomatous polyposis patients., Cancer Epidemiol. Biomarkers Prev.

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Ferner et al., 1991, The effects of enalapril and sulindac on the dermal response to substance P and neurokinin A., Br J Clin Pharmacol

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Publications:

Wilson et al., 2002, Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention., Cancer Res.

Interaction Types & Directionality:

n/a

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Interaction Types & Directionality:

n/a

Alternate Names:

SULINDAC DrugBank Drug Name

38194-50-2 CAS Number

Apo-sulin Tab 150mg Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Alternate Names:

SULINDAC Primary Drug Name

Drug Info:

Year of Approval 1978

Drug Class anti-inflammatory agents, non-steroidal

Drug Info:

Drug Indications NSAID

Drug Class small molecule

FDA Approval 1978

Alternate Names:

C850 NCI drug code

Alternate Names:

CHEMBL15770 ChEMBL Drug ID

Publications:

Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

Wang ZG et al., 2013, Synthesis and SAR study of modulators inhibiting tRXRα-dependent AKT activation., Eur J Med Chem

Alternate Names:

SULINDAC GuideToPharmacology Ligand Name

Alternate Names:

D0Z5IU TTD Drug ID